
- Pharmaceutical Executive-03-01-2009
- Volume 0
- Issue 0
Wishbone for Barrier Thearpeutic's Vusion
It's not unusual for creative teams to ask actors to work up on-screen tears. But when you go from crying actors to crying babies, it makes all the difference.
CRYING BABY
Wishbone
BRAND Vusion CLIENT Barrier Therapeutics FROM LEFT: Renee Mellas, partner, general manager; Scott Sager, senior vice president, creative director; Steve Hamburg, partner, chief creative officer
It's not unusual for creative teams to ask actors to work up on-screen tears. But when you go from crying actors to crying babies, it makes all the difference. That crying baby formed the basis of the print and television campaign Wishbone created for Barrier Therapeutics' anti-fungal pediatric ointment Vusion. "It's wired into parents as an incentive to action," says Steve Hamburg, partner/chief creative officer. "These are things that get parents' attention almost genetically."
The accompanying creative keeps consistent with the esthetic of "baby-ness." "It's time for a change" was used as a pun on the double meaning of the dirty diaper and the therapy.
Hamburg says that the DTC spot was so effective that it produced a dramatic increase in prescriptions for the drug.
Articles in this issue
about 17 years ago
GSW Worldwide for MGI Pharma/Eisai's PONVabout 17 years ago
Topin & Associates for Dusa's ClindaReachabout 17 years ago
Saatchi & Saatchi for Sanofi-Aventis's Ambien CRabout 17 years ago
Through the Looking Glassabout 17 years ago
Fifth Annual Press Audit: Safety in the Spotlightabout 17 years ago
Torre Lazur McCann for BMS & Sanofi Aventis's Plavixabout 17 years ago
ICC for Sanofi Pasteur's TravelWise Programabout 17 years ago
The New Sales Forceabout 17 years ago
Flashpoint Medica for Indevus Pharmaceuticals's Supprelin LAabout 17 years ago
TBWA\WorldHealth for Schering-Plough's NuvaRingNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.




